The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

In a recent SEAS study, it was determined that the cholesterol reducing drug, Vytorin, did not prevent worsening of heart valve disease or lower the need for valve surgery.

Preliminary results showed that Vytorin, a combination of Zocor and Zetia, was no better than placebos at lowering the risk of major cardiovascular events, including heart attack, stroke, heart surgery and death in patients with aortic stenosis, although it did cut cholesterol levels about 60 percent.

Vytorin did however cut cholesterol levels about 60 percent

Comments are closed.

Of Interest